Logo image of NKTR

NEKTAR THERAPEUTICS (NKTR) Stock Fundamental Analysis

NASDAQ:NKTR - US6402681083 - Common Stock

27.14 USD
+0.11 (+0.41%)
Last: 8/25/2025, 8:00:01 PM
27.16 USD
+0.02 (+0.07%)
After Hours: 8/25/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NKTR. NKTR was compared to 193 industry peers in the Pharmaceuticals industry. NKTR may be in some trouble as it scores bad on both profitability and health. NKTR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NKTR had negative earnings in the past year.
NKTR had a negative operating cash flow in the past year.
In the past 5 years NKTR always reported negative net income.
In the past 5 years NKTR always reported negative operating cash flow.
NKTR Yearly Net Income VS EBIT VS OCF VS FCFNKTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

The Return On Assets of NKTR (-58.92%) is worse than 64.77% of its industry peers.
Industry RankSector Rank
ROA -58.92%
ROE N/A
ROIC N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
NKTR Yearly ROA, ROE, ROICNKTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

The Gross Margin of NKTR (83.44%) is better than 88.60% of its industry peers.
NKTR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NKTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
NKTR Yearly Profit, Operating, Gross MarginsNKTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NKTR has been reduced compared to 1 year ago.
Compared to 5 years ago, NKTR has more shares outstanding
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NKTR Yearly Shares OutstandingNKTR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NKTR Yearly Total Debt VS Total AssetsNKTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

NKTR has an Altman-Z score of -24.73. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
NKTR's Altman-Z score of -24.73 is on the low side compared to the rest of the industry. NKTR is outperformed by 82.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.73
ROIC/WACCN/A
WACC9.96%
NKTR Yearly LT Debt VS Equity VS FCFNKTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.61 indicates that NKTR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.61, NKTR is in line with its industry, outperforming 47.67% of the companies in the same industry.
NKTR has a Quick Ratio of 2.61. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.61, NKTR is in line with its industry, outperforming 51.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.61
NKTR Yearly Current Assets VS Current LiabilitesNKTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

2

3. Growth

3.1 Past

NKTR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.70%, which is quite good.
Looking at the last year, NKTR shows a very negative growth in Revenue. The Revenue has decreased by -19.52% in the last year.
Measured over the past years, NKTR shows a decrease in Revenue. The Revenue has been decreasing by -3.00% on average per year.
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.33%
Revenue 1Y (TTM)-19.52%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-52.42%

3.2 Future

NKTR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.28% yearly.
Based on estimates for the next years, NKTR will show a small growth in Revenue. The Revenue will grow by 3.25% on average per year.
EPS Next Y-2.89%
EPS Next 2Y-3.06%
EPS Next 3Y-7.33%
EPS Next 5Y-0.28%
Revenue Next Year-57.12%
Revenue Next 2Y-35.95%
Revenue Next 3Y-30.7%
Revenue Next 5Y3.25%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NKTR Yearly Revenue VS EstimatesNKTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
NKTR Yearly EPS VS EstimatesNKTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 20 -20 40 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NKTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NKTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTR Price Earnings VS Forward Price EarningsNKTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTR Per share dataNKTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

NKTR's earnings are expected to decrease with -7.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.06%
EPS Next 3Y-7.33%

More info and screens

0

5. Dividend

5.1 Amount

NKTR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEKTAR THERAPEUTICS

NASDAQ:NKTR (8/25/2025, 8:00:01 PM)

After market: 27.16 +0.02 (+0.07%)

27.14

+0.11 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners62.34%
Inst Owner Change-92.71%
Ins Owners0.96%
Ins Owner Change-1.08%
Market Cap516.20M
Analysts81.43
Price Target98.09 (261.42%)
Short Float %6.22%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.26%
Min EPS beat(2)-43.22%
Max EPS beat(2)4.71%
EPS beat(4)3
Avg EPS beat(4)-3.86%
Min EPS beat(4)-43.22%
Max EPS beat(4)16.31%
EPS beat(8)4
Avg EPS beat(8)-6.67%
EPS beat(12)7
Avg EPS beat(12)-0.65%
EPS beat(16)11
Avg EPS beat(16)3.16%
Revenue beat(2)1
Avg Revenue beat(2)-16.16%
Min Revenue beat(2)-33.31%
Max Revenue beat(2)0.98%
Revenue beat(4)2
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-33.31%
Max Revenue beat(4)29.38%
Revenue beat(8)6
Avg Revenue beat(8)12.89%
Revenue beat(12)8
Avg Revenue beat(12)8.48%
Revenue beat(16)8
Avg Revenue beat(16)4.95%
PT rev (1m)1.41%
PT rev (3m)1855.92%
EPS NQ rev (1m)-0.66%
EPS NQ rev (3m)-1299.88%
EPS NY rev (1m)-0.83%
EPS NY rev (3m)-1424.88%
Revenue NQ rev (1m)-6.97%
Revenue NQ rev (3m)-54.03%
Revenue NY rev (1m)-1.4%
Revenue NY rev (3m)-23.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.65
EYN/A
EPS(NY)-12.43
Fwd EYN/A
FCF(TTM)-9.78
FCFYN/A
OCF(TTM)-9.72
OCFYN/A
SpS3.94
BVpS-1.27
TBVpS-1.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.44%
FCFM N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
F-Score3
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.24%
Cap/Sales 1.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.61
Altman-Z -24.73
F-Score3
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)29.45%
Cap/Depr(5y)49.23%
Cap/Sales(3y)2.88%
Cap/Sales(5y)5.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.33%
EPS Next Y-2.89%
EPS Next 2Y-3.06%
EPS Next 3Y-7.33%
EPS Next 5Y-0.28%
Revenue 1Y (TTM)-19.52%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-52.42%
Revenue Next Year-57.12%
Revenue Next 2Y-35.95%
Revenue Next 3Y-30.7%
Revenue Next 5Y3.25%
EBIT growth 1Y-2.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.83%
EBIT Next 3Y-10.5%
EBIT Next 5YN/A
FCF growth 1Y24.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.22%
OCF growth 3YN/A
OCF growth 5YN/A